Skip to main content

Table 2 Seroprevalence (%)

From: A hepatitis A, B, C and HIV prevalence and risk factor study in ever injecting and non-injecting drug users in Luxembourg associated with HAV and HBV immunisations

   OTC
N/Ntotal
ITC
N/Ntotal
PC
N/Ntotal
IDUs
N/Ntotal
nIDUs %
N/Ntotal
  Active HBV
(HBs ag+)
1.5
2/130
0
0/54
7.0
8/115
3.9
10/254
0
0/45
HBV
(cured or active infection)
Cured HBV
(HBs ab+, HBc ab+)
13.1
17/130
14.8
8/54
23.5
27/115
19.3
49/254
6.7
3/45
  Total HBVab * 22.3
29/130
16.7
9/54
34.8
40/115
29.1
74/254
8.9
4/45
HBV vaccination (HBs ab+) 39.2
51/130
57.4
31/54
45.2
52/115
46.1
117/254
37.8
17/45
HBV seropositivity (all types) 61.5
80/130
74.1
40/54
80.0
92/115
75.2
191/254
46.7
21/45
HCV (Elisa +, RIBA +)
HCVab
57.3
75/131
75.4
46/61
86.3
107/124
81.3
218/268
19.1
9/47
HAV (IgG+)
HAVab
54.7
70/128
57.1
24/42
68.3
41/60
57.1
108/189
65.9
27/41
HIV-1
HIVab
1.5
2/130
0
0/49
7.7
5/65
2.5
5/202
4.8
2/42
  1. *Including 18 cases with HBc antibody only.